Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Single-blind, Controlled Trial of Topical Fibrocaps in Intraoperative Surgical Hemostasis

Next Previous
Trial Profile

A Phase 3, Randomized, Single-blind, Controlled Trial of Topical Fibrocaps in Intraoperative Surgical Hemostasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fibrinogen/thrombin (Primary) ; Gelatin
  • Indications Surgical blood loss
  • Focus Registrational; Therapeutic Use
  • Acronyms FINISH-3
  • Sponsors ProFibrix

Most Recent Events

  • 30 Apr 2015 Based on the results of this trial, the US FDA has approved Raplixa (fibrin sealant) and the RaplixaSpray device to provide adjunctive haemostasis for mild to moderate bleeding in adults undergoing surgery when control of bleeding by standard surgical techniques is ineffective or impractical, according to a media release from The Medicines Company.
  • 30 Mar 2015 According to a media release from The Medicines Company, the EC has granted marketing authorization for fibrinogen/thrombin [Raplixa], followed by positive opinion by the CHMP of the EMA.
  • 28 Oct 2014 Results published in a media release from The Medicines Company.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top